RESUMOO objetivo foi comparar a objetividade e verificar a replicabilidade de análises computacionais do tempo-movimento (ATM) e técnico-táticas de judô por diferentes níveis de expertise. Participaram 22 sujeitos (12 praticantes, separados em 6 experts e 6 não-experts, e 10 não-praticantes). Os indivíduos qualificaram o software via questionário e realizaram 150 análises (90=comparações inter-grupos; 60=comparações intra-grupo). Os dados foram comparados por Friedman e Wilcoxon, e correlacionados por Coeficiente Kappa de Cohen, p< 0,05. Não foram observadas diferenças entre os grupos quando comparados indicadores de qualidade, que mostraram melhores percentuais em resposta "o tempo todo" que em respostas "na maior parte do tempo", "parte do tempo" e "nunca ou não" (p<0,001). As correlações mostraram concordância "forte" da ATM (índice=0,76) para os três grupos, porém concordância "fraca" das análises técnico-táticas entre praticantes e não-praticantes (índice=0,08). Em conclusão, ATM apresentou replicabilidade nos três grupos; para análises técnico-táticas é necessário conhecimento específico de judô. Palavras-chave: Artes marciais. Tecnologia. Desempenho esportivo. Controle motor. ABSTRACTThe objective was to compare the objectivity and to verify the applicability of computational time-motion analysis (TMA) and technical-tactical analysis of judo for different levels of expertise. The sample was composed by 22 subjects (12 practitioners, separated into six experts and six non-experts, and 10 non-practitioners). The sample qualified the software via questionnaire and they conducted 150 analysis (90 = inter-group comparisons; 60 = intra-group comparisons). Data were compared by Wilcoxon and Friedman, and by Kappa Cohen coefficient, p <0.05. No differences were observed between groups when compared the quality indicators, which showed better percentage in response "all the time", when compared with the responses "most of the time", "part time" and "never or not" (p <0.001 ). The correlations showed "strong" concordance (index = 0.76) in TMA for the three groups, but a "weak" agreement (index = 0.08) of technical-tactical analysis between practitioners and non-practitioners. In conclusion, TMA presented replicability in the three groups; for technicaltactical analysis it is required a specific knowledge of judo. Keywords: Martial arts. Technology. Sport performance. Motor control. IntroduçãoA análise técnico-tática é um meio utilizado para compreender o modo pelo qual as habilidades esportivas são desempenhadas, o que pode fornecer informações para promover o desempenho na prática específica 1 . Enquanto a análise tempo-movimento (ATM) permite obter informações que revelam inferências sobre o esforço específico requerido nas tarefas realizadas 2,3 . Essas análises auxiliam tanto o planejamento de treinamento quanto o desenvolvimento de avaliações com ações motoras e solicitação metabólica análogas às da modalidade em relação aos componentes anaeróbio e aeróbio do atleta 4,5,6,7 . Diferentes trabalhos com ATM e de ...

Objectives: The economical crisis and the requirements for structural changes in all aspects of public health brought a new era of reforms in the country as well as the health care system itself. The Pharmaceutical Legislation, both European and national, were implemented to protect public and state interests. Application of new legislation influenced provider of health care services in different areas. Therefore it is important to evaluate the impact and performance on costs and revenues of health care services provider. MethOds: Monitoring, calculation and assessment of costs and revenues with the help of financial analysis indicators for years 2003-2012, using financial statements was conducted, with respect to profitability, debt, liquidity, working capital and efficiency ratios. These ratios constituted significant information of implementing new health care legislation and price policies. Results: In case of profitability, parameter gross profit ranged from x 2003-2011 = 16.1-22.8% (x average = 19.2%, X mean = 19.8%, σ = 2.4), but in 2012 decreased on 14.3%. Net profit ranged x 2003-2011= 12.8-18.3% (x average = 14.6%, X mean = 16.6%, σ = 4.9%), while in 2012 reached only 2.3%. Debt parameters varied from x 2003-2012= 2.33-4.8 (x average = 3.44, X mean = 3.06, σ = 0.82), liquidity parameters current ratio x 2003-2012 = 1.1-1.7 (X average = 1.43, X mean = 1.45, σ = 0.15) and quick ratio x 2003-2012= 0.7-1.3 (x average = 1.16, x mean = 1.09, σ = 0.15), working capital ratio x 2003-2012 = 2,7-12,9, (X average = 9.6, X mean = 10.1, σ = 3.1) and efficiency ratios were measured either. cOnclusiOns: Implementation of new health care legislation and price policy that were intended to apply restrictive measures to increase system efficiency and cost savings had a significant impact on health care services providers by worsening profitability and liquidity parameters as key indicators of provider stability. Despite the improvement in debt ratio, working capital ratio and efficiency ratios, stability may be threatened and may affect the amount of health care services providers. PHP265 THe effecT of DecenTraliseD Public HealTH care Provision on accessibiliTy To MeDicines in bosnia anD HerzegovinaMelck B. , Ando G. , Izmirlieva M. IHS, London, UKObjectives: This study aims to assess the extent of the restriction on access to medicines in Bosnia and Herzegovina in relation to the country's decentralised provision of health care, with three separate state entities and 10 cantons within the federation of Bosnia and Herzegovina all having a role in the provision of public health care. MethOds: A comparison was made between the contents of the federal essential drug list and the drug lists of the various entities and cantons, in order to ascertain which medicines were available, at what price, and with what level of reimbursement. Results: The federal essential list contains the basic INNs which must be provided by each canton, but there were some important differences between the lists of the various entities and cantons. F...

lating health outcomes were reported in two-thirds of the submissions. However, worst-case scenarios were hardly presented. Compliance with HAS guidelines for exploring methodological uncertainty (e.g. perspective, discounting, time horizon) was fair. However, the choice of the comparator(s)-an essential component of a CEA-was considered problematic in nearly 40% of submissions. ConClusions: Overall, reporting of DSA and PSA is complying with HAS guidelines. More work is needed to explore uncertainty, in particular, to account for correlations between model input parameters and to enhance the analysis of structural uncertainty.

A457and European countries. Methods: Comparison of miligram based prices analysis between European countries done by Intelligent Health System(IHS) was used. The analysis of IHS included Germany, France, United Kingdom(UK), Spain and Italy(EU5). Comparison was done with taken row data of analysis EU5 and Turkey average milligram retail prices of Ceftriaxone, Clopidogrel, Esomeprazole, Fentanyl, Lamotrigine, Levofloxacin, Metformin, Venlafaxine, Letrozole and Olanzapine molecules. Results: It has been reported that compared 10 molecules highest average miligram based prices of Esomeprazole(0,043 € ), Levofloxacin(0,058 € ) and Clopidogrel(0,0083 € ) molecules belong to Turkey, Lamotrigine(0,01 € ) belongs to Germany. The highest average miligram based prices of other 6 molecules belong to UK with following; Ceftriaxone(0,0196 € ), Fentanyl(0,186 € ), Letrozole(1,24 € ), Metformine(0,00013 € ), Venlafaxine(0,0074 € ), Olanzapine(0,261 € ). ConClusions: It has known that because of UK used free pricing mechanism on drugs, prices of drugs are higher than other compared countries. This sitiuation established on the anaylsis. But despite of Turkish Government policy decisions; it is important indiciation that 3 drugs represents highest prices out 10 drugs. Reference pricing system applied based on box price. Better control mechanism may achievable if miligram based pricing apply in Turkey. On the other hand because of the study only consist retail sales prices the evaluation should be done from point of reimbursement prices on future studies.

A445 Objectives: Gemeinsame Bundesausschuss (G-BA) states that it assesses additional benefit strictly on clinical grounds, but it also requires that manufacturers submit drug and comparator costs. This raises the possibility that G-BA's assessment might be influenced by price, possibly to provide leverage during subsequent price negotiations. This research tests the hypothesis that high cost drugs (relative to the comparator) are more likely to receive poor benefit assessments. MethOds: The following variables were collected from the Federal Gazette publication or the "Beschluss" document: additional benefit assessment, annual cost per patient of drug and comparator, and estimated target population. The Scottish Medicines Consortium (SMC) clinical rationale for the same drugs and indications were collected to control for clinical efficacy. After excluding orphan drugs, reviews using best supportive care comparators, and reviews without SMC reviews, 58 reviews remained for analysis. G-BA's additional benefit assessments were ranked from least benefit to most. The influence of drug cost relative to the comparator on the G-BA assessment was estimated via an ordered logit model. The model also included controls for the (log) size of the target population and clinical efficacy (SMC's clinical assessment). Results: An increase in the cost difference between the drug and the comparator is estimated to result in a modest, statistically significant increase in the odds of receiving an additional benefit assessment greater than a "no additional benefit" assessment. cOnclusiOns: Our results are inconsistent with the alternative hypothesis that G-BA is strategically discounting its assessment of relatively high cost drugs. The positive estimated relationship is consistent with manufacturers' setting higher prices for more beneficial drugs (The data available provide no way to statistically account for this plausible source of endogeneity). Our results provide no support for rejecting the null hypothesis that G-BA assesses added benefit independently of drug cost.